DSS has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of the Company’s wholly-owned subsidiary, Impact Biomedical. DSS, Inc. intends to list Impact Biomedical on the NYSE American exchange. The number of shares of Class A common stock to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market conditions. The Company has engaged Aegis Capital as the exclusive placement agent for the registered direct offering. A registration statement on Form S-1 relating to these securities has been filed with the SEC and has yet to become effective.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DSS:
- DSS, Inc. Announces Filing of Registration Statement on Form S-1 for Initial Public Offering of Impact Biomedical
- DSS Inc. Issues Letter to Shareholders
- DSS CEO looking forward to ‘significant growth’ for remainder of the year
- TD Cowen packaged foods analysts holds analyst/industry conference call
- DSS subsidiary appoints Jim Monaghan as COO and Chief Compliance Officer